AVCT
NEUTRALAvacta Announces Board Change
The healthcare company announces the retirement of a non-executive director and the appointment of a new chair for the Remuneration Committee.
Avacta Group
32.75GBX
-2.24%
Market Cap
126.74M
Volume
1.44M
75% of avg
P/E Ratio
-0.03
EPS (TTM)
-9.46
Beta
-0.17
Day Range
32.50p - 34.98p
52 Week Range
28.83p32.75p86.40p
32.75p
Upcoming Events
AVCT
NEUTRALAvacta presents preclinical data on FAP-EXd candidate at AACR
The biotechnology company presents preclinical data on its FAP-EXd candidate and insights on the pre|CISION platform at the AACR Annual Meeting.
AVCT
NEUTRALAvacta Presents Promising Phase 1 Data for Lead Cancer Drug Candidate
The biotechnology company reports positive early-stage trial data for its lead cancer drug candidate, highlighting signs of efficacy and a favorable safety profile.
AVCT
NEUTRALAvacta Raises Funds to Settle Convertible Bond Obligations
The biotechnology company is issuing new shares to settle quarterly payments on its convertible bond, maintaining cash for its drug development pipeline.
AVCT
NEUTRALAvacta Provides Quarterly Update on Pipeline Progress
The biotechnology company updates on the progress of its pipeline, including the advancement of its FAP-Dox and FAP-EXd drug candidates.
AVCT
NEUTRALAvacta to Present at AACR Annual Meeting
The biotechnology company will have three presentations at the upcoming AACR Annual Meeting, showcasing data from its proprietary pre|CISION platform and pipeline of peptide drug conjugates.
AVCT
NEUTRALAvacta to Present at Leerink Healthcare Conference
The biotechnology company will present at an upcoming healthcare conference.
AVCT
GOODAvacta Advances Cancer Drug AVA6000 with Promising Early Data
The biotechnology company reports promising early data for its cancer drug AVA6000, with high disease control rates and favorable safety in Phase 1 trials.
AVCT
GOODAvacta Sharpens Focus on Therapeutics with Diagnostics Sale
The life sciences company is selling its UK diagnostics unit to become a pure-play therapeutics business, with proceeds to fund R&D on promising cancer drug candidates.
AVCT
NEUTRALAvacta Group Appoints New Joint Broker
The healthcare company has appointed a new joint broker to work alongside its existing broker, a routine regulatory update.